Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
18/100
Pipeline Velocity
6/100
Trial Completion Rate
100/100
Pipeline Concentration
100/100
Pipeline Freshness
63/100
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Lac-Hydrin — AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
Application NDA006580 (NDA)
Lac-Hydrin — AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE
Application NDA006580 (NDA)
Lac-Hydrin — LAC-HYDRIN
Application NDA019155 (NDA)
Lac-Hydrin — LAC-HYDRIN
Application NDA019155 (NDA)
Lexette — ULTRAVATE
Application NDA019967 (NDA)
Lexette — ULTRAVATE
Application NDA019968 (NDA)
Lac-Hydrin — LAC-HYDRIN
Application NDA020508 (NDA)
Lac-Hydrin — LAC-HYDRIN
Application NDA020508 (NDA)
Lexette — ULTRAVATE
Application NDA208183 (NDA)
Lexette — BRYHALI
Application NDA209355 (NDA)
Lexette — LEXETTE
Application NDA210566 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)